Controversies in the Treatment of Wet Age-related Macular Degeneration

[...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences between both treatments in efficacy.1-2 In this case, countries such as Italy, Germany, Austria, Finland, and New Zealand, is formally recommended to use bevacizumab instead of ranibizumab in AMD, while waiting for a head-to-head trial, which had to be promoted by independent organizations.